GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Other Net Income (Loss)

Cannara Biotech (TSXV:LOVE) Other Net Income (Loss) : C$1.96 Mil (TTM As of Feb. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Other Net Income (Loss)?

Cannara Biotech's Other Net Income (Loss) for the three months ended in Feb. 2025 was C$0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Feb. 2025 was C$1.96 Mil.

Cannara Biotech's quarterly Other Net Income (Loss) declined from Aug. 2024 (C$1.95 Mil) to Nov. 2024 (C$0.00 Mil) but then increased from Nov. 2024 (C$0.00 Mil) to Feb. 2025 (C$0.00 Mil).

Cannara Biotech's annual Other Net Income (Loss) stayed the same from Aug. 2022 (C$0.00 Mil) to Aug. 2023 (C$0.00 Mil) but then declined from Aug. 2023 (C$0.00 Mil) to Aug. 2024 (C$-0.00 Mil).


Cannara Biotech Other Net Income (Loss) Historical Data

The historical data trend for Cannara Biotech's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Other Net Income (Loss) Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Other Net Income (Loss)
Get a 7-Day Free Trial - - - - -

Cannara Biotech Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.95 - -

Cannara Biotech Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannara Biotech Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Nicholas Sosiak Senior Officer
Donald John Olds Director
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director
Scott Carroll Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot Director, Senior Officer
Brian Sherman Senior Officer
Avi Krivorot Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer Senior Officer
Jack M. Kay Director
Donal Carroll Director or Senior Officer of 10% Security Holder